Sagimet Biosciences Inc. (SGMT)

NASDAQ: SGMT · Real-Time Price · USD

5.43

-0.02 (-0.37%)

Mar 6, 2026, 9:36 AM EST - Market open

Sagimet Biosciences Employees

Sagimet Biosciences had 14 employees as of December 31, 2024. The number of employees increased by 4 or 40.00% compared to the previous year.

Employees

14

Change (1Y)

4

Growth (1Y)

40.00%

Revenue / Employee

n/a

Profits / Employee

-$4,119,357

Market Cap

176.59M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	14	4	40.00%
Dec 31, 2023	10	0	-
Dec 31, 2022	10	3	42.86%
Dec 31, 2020	7	-	-

Related Stocks

Company Name	Employees
ProQR Therapeutics	166
Nkarta	105
Vaxart	105
Tenaya Therapeutics	97
Tonix Pharmaceuticals Holding	81
Cartesian Therapeutics	66
SAB Biotherapeutics	63
Tiziana Life Sciences	9

Employee Rankings

SGMT News

2 days ago - Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript - Seeking Alpha
9 days ago - Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - GlobeNewsWire
4 weeks ago - Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - GlobeNewsWire
4 weeks ago - Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne - GlobeNewsWire
5 weeks ago - Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne - PRNewsWire
5 weeks ago - Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor - GlobeNewsWire
2 months ago - Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - GlobeNewsWire
2 months ago - Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market - Seeking Alpha